Active IgG4-related disease with bone marrow involvement: a report of 2 cases and case-based review

Shiyi Liu¹,²,³, Hui Wang⁴ and Tao Su¹,²*

Abstract
IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory disease, histopathologically characterized by dense lymphoplasmacytic infiltration rich in IgG4-positive plasma cells in affected organs. Classic hematologic presentations including lymphadenopathy, eosinophilia and polyclonal hypergammaglobulinemia are common, whereas bone marrow involvement of IgG4-RD is rarely reported. Here we present two patients of multi-organ IgG4-RD with bone marrow involvement, one on bone marrow biopsy, and the other on PET/CT. Presentations of other organ involvement included biopsy-proven IgG4-related tubulointerstitial nephritis, lymphadenopathies, submaxillary glands, arthritis, asthma, dysosmia, and constitutional symptoms. Bone marrow involvement was initially suspected due to leukopenia, anemia and thrombocytopenia in case#1, and was finally confirmed by histological evidence of significant IgG4-positive plasma cells infiltration in bone marrow. In case#2, we incidentally observed high uptakes of multi-bone marrow on ¹⁸F-FDG-PET/CT, with the maximum SUV value similar to that of the kidneys, submaxillary glands and hilar mediastinal lymph nodes by ¹⁸F-FDG-PET/CT. Symptoms and all the hematologic presentation improved rapidly in both patients after steroids initiation. These two cases illustrate the rare bone marrow involvement in active IgG4-RD accompanied by other hematologic syndromes. The significance of disease pathogenesis is worthy of further study.

Keywords: IgG4-related disease, Bone marrow, Hematologic, Leukopenia, Thrombocytopenia, ¹⁸F-FDG-PET/CT

Introduction
IgG4-related disease (IgG4-RD) is a fibro-inflammatory condition recognized for decades, characterized by multi-organ enlargement with histopathological dense lymphoplasmacytic infiltration rich in IgG4-positive plasma cells, storiform fibrosis and obliterative phlebitis. IgG4-RD was first reported in patients with autoimmune pancreatitis (AIP) and it was gradually recognized as a systemic immune disease over the following years [1, 2]. Usually, most patients with IgG4-RD present with polyclonal hypergammaglobulinemia, which is typically caused by elevation of serum IgG4 [3]. Additionally, elevated serum IgG4 is much more common in Asian patients than patients of European descent [4, 5]. Nearly all the tissues can be involved, especially the pancreas, salivary glands, biliary duct, liver and kidneys. Hematologic manifestations of IgG4-RD have also been recognized, such as lymphadenopathy [6]. But case reports of bone marrow (BM) involvement were rare.

Here, we present two patients of IgG4-RD with bone marrow involvement. One patient had significant IgG4-positive plasma cells infiltration in bone marrow aspiration and biopsy samples. In the other patient, hematologic involvement was detected by ¹⁸ fluorodeoxyglucose positron emission tomography (¹⁸F-FDG-PET/CT), showing high uptakes in multi-bone marrow. These
reports suggest the possibility of hematologic pathogenesis of IgG4-RD.

**Materials and methods**

**Case presentation**

Case 1 was a 68-year-old Chinese male who complained of upper abdominal pain with aggravation of renal function. He had a 2-year history of repeated upper abdominal pain suspected as “ileus” and suffered frequent attacks during the last 9 months. The patient developed acute kidney injury initially as serum creatinine (Scr) was insidiously elevated from 270 to a peak of 410 μmol/L, and went back to normal range after supportive treatment. However, symptoms relapsed 2 weeks before his hospital admission to Peking University First Hospital. The abdominal enhanced-CT scan revealed swelling kidneys with renal parenchyma patchy filling defects, and dilated small bowel loops. Thickening of the abdominal aorta, superior mesenteric and splenic artery walls could also be recognized (Fig. 1).

Laboratory testing details on admission are shown in Table 1. The patient had mild leukopenia, anemia and thrombocytopenia. The Scr was 326 μmol/L in the presence of mild proteinuria. The serum protein electrophoresis showed polyclonal hypergammaglobulinemia (IgG 29.56 g/L, IgG4 11.7 g/L), and no monoclonal band was detected. 18F-FDG-PET/CT scan showed high uptakes in bilateral submaxillary glands, kidneys, hilar and mediastinal lymph nodes (Table 1, Fig. 2). In contrast, abdominal aorta, superior mesenteric, splenic arteries and bone marrow showed no hypermetabolic lesions.

The patient underwent a right kidney biopsy. Renal pathology disclosed ischemic sclerotic glomeruli (19/28, 67.9%) with mild mesangial proliferation and typical IgG4-related tubulointerstitial nephritis. The ratio of IgG4/IgG was 65% (Fig. 3) in immunohistologic staining. Renal fibrosis was remarkable and “storiform” fibrosis existed in the local area. The formation of an ectopic germinal center was found. He also had a posterior superior iliac spine bone marrow examination because of unexplained leukopenia and thrombocytopenia. Analysis of bone marrow could exclude hematologic malignancies. Bone marrow proliferation was active. Granulocyte lines accounted for 65.5%, with the ratio of granulocyte to erythroid at 2.5:1. Five megakaryocytes could be seen in the whole BM smear (2.0 × 0.5 cm), and no plasma cell was observed in BM aspirate. In BM biopsy, we found CD138 and IgG-positive plasma cells were scattered in the BM interstitium with some eosinophils, and 50% of these IgG-positive plasma cells were also positive for IgG4 (IgG 40/HP, IgG4 20/HP). The plasma cells presented weak positives for kappa and lambda light chains (Fig. 3). Together, the diagnosis of IgG4-RD was confirmed with six sites involved and constitutional symptoms. The patient was prescribed prednisolone 40 mg/day. Symptoms were relieved soon after prednisolone initiation. The peripheral blood cell count returned to normal. Scr declined to 240 μmol/L one month after hospital discharge and remained at 180 μmol/L during the subsequent year.

Case 2 was a 38-year-old male referred to the nephrology clinic for investigation of renal insufficiency as his serum creatinine was 146 μmol/L. He presented severe fatigue, dysosmia and conspicuous weight loss of 11 pounds during the last 2 months. He had a history of anaphylactic rhinitis and bronchial asthma. On admission, blood pressure was 150/90 mmHg, physical examination revealed bilateral submaxillary gland swelling with left supraclavicular lymphadenopathy, and these were later confirmed by ultrasonography and FDG-PET/CT scan.

Laboratory tests are summarized in Table 1. It showed obvious eosinophilia with normal WBCs and platelet count. There was a remarkable hyperglobulinemia (IgG 64.8 g/L, IgG4 47.2 g/L, IgE 1761 kU/L). No
monoclonal immunoglobulin was detected by immunofixation electrophoresis from serum and urine. $^{18}$F-FDG-PET/CT showed high uptakes in bilateral submandibular glands, kidneys and bilateral scapula, spine, sternum, ribs, pelvis, and upper femur (Fig. 2), indicating signs of IgG4-relating lesions including bone

### Table 1 Clinical, laboratory and radiological findings in two IgG4-RD patients

|                          | Case 1                      | Case 2                      |
|--------------------------|-----------------------------|-----------------------------|
| **IgG4-related clinical symptoms** | AKI, AKD on CKD             | AKD                         |
|                          | Ileus                       | Asthma, rhinitis            |
|                          | Fatigue                     | Fatigue, weight loss        |
| **IgG4-RD involved organs, identified by** | Kidneys (13.0 × 6.3 × 5.8/12.2 × 5.9 × 4.5) | Kidneys (13.0 × 7.5 × 6.4/13.3 × 6.6 × 5.7) |
| Clinical presentation/enhanced-CT/US (measured by US, cm$^3$) | Submaxillary glands         | Submaxillary glands         |
|                          | Abdominal aortitis          |                             |
|                          | Superior mesenteric, splenic arteritis |                             |
| **Pathology**            | Kidney (right)              | Kidney (right)              |
|                          | Bone marrow                 | ND                          |
| **FDG-PET/CT (SUV max)** | Kidneys (5.0)               | Kidneys (3.7)               |
|                          | Submaxillary glands (3.0)   | Submaxillary glands (2.9)   |
|                          | Hilar, mediastinal lymph nodes (4.0) | Hilar, mediastinal lymph node (3.5) |
|                          | Bone marrow                 | Bone marrow (3.6)           |
| **Number of involved sites** | 6                          | 6                           |
| **Laboratory data**      |                             |                             |
| WBC (3.5–9.5 × 10$^9$/L) | 3.4                         | 4.2                         |
|                          | NE (40.0–79.0%)             | 60.8                        | 54.8                        |
|                          | LY (20.0–50.0%)             | 27.2                        | 18.8                        |
|                          | EO (0.4–8.0%)               | 4.0                         | 15.0                        |
| Platelet count (125–350 × 10$^9$/L) | 110                      | 173                         |
| Hemoglobin (130–175 g/L) | 108                         | 122                         |
| Total protein (65–85 g/L) | 73.1                        | 99.5                        |
| Albumin (40–55 g/L)      | 34.3                        | 36.7                        |
| BUN (1.8–7.1 mmol/L)     | 17.27                       | 7.2                         |
| Creatinine (44–133 μmol/L) | 326                   | 146                         |
| Amylase (35–135 IU/L)    | 219                         | ND                          |
| C3 (0.6–1.5 g/L)         | 0.519                       | 0.486                       |
| C4 (0.12–0.36 g/L)       | 0.15                        | 0.113                       |
| IgG (7.23–16.85 g/L)     | 29.56                       | 64.77                       |
| IgG1 (4.90–11.40 g/L)    | 8.35                        | 12.60                       |
| IgG2 (1.69–7.86 g/L)     | 8.01                        | 3.57                        |
| IgG3 (0.11–0.86 g/L)     | 1.50                        | 1.40                        |
| IgG4 (0.03–2.01 g/L)     | 11.70                       | 47.20                       |
| IgA (0.69–3.82 g/L)      | 2.33                        | 1.01                        |
| IgM (0.63–2.77 g/L)      | 0.50                        | 0.57                        |
| IgE (< 100 kU/L)         | ND                          | 1761                        |
| hs-CRP (0.0–3.0 mg/L)    | 8.56                        | 9.99                        |
| ESR (0–15 mm/h)          | 52                          | 92                          |
| Urinary protein (0–0.15 g/day) | 0.53                | 0.41                        |
| ANA                       | 1:3200                      | <1:100                      |
| dsDNA (IU/mL)            | 262                         | <1:10                       |
| Lymphocytes T CD4$^+$ (34.0–70.0%) | ND                   | 38.26                       |
| Lymphocytes T CD8$^+$ (14.0–41.0%) | ND                   | 57.46                       |

AKI acute kidney injury, AKD acute kidney disease; ND, no data; US ultrasonography
marrow. Kidney pathological findings showed that all glomeruli were mildly changed without immune deposits on immunofluorescence. There were massively infiltrated inflammation cells in the renal interstitium including lymphocytes, plasma cells and eosinophils, as well as diffuse interstitial fibrosis accompanied by local storiform fibrosis. IgG4 to IgG-positive plasma cells were 40% (Fig. 3). A diagnosis of IgG4-related tubulo-interstitial nephritis was made.

The patient was initiated on prednisolone combined with plasmapheresis. Four weeks later when he was dismissed from hospital, his IgG4 decreased to 1.49 g/L and Scr to 108 μmol/L. Two doses of Rituximab 375 mg/m² with a 4-week interval were infused. The patient currently remained stable for 2 years.

Discussion

IgG4-RD is a systemic disease characterized by largely consistent pathomorphological manifestations across a wide range of organ systems. We call it a pathologically fibro-inflammatory pattern with enlarged organs or tissues. With the increasing number of reports and research in this field, clinicians have gradually become familiar with this syndrome. IgG4-related bone marrow presentation has rarely been mentioned before [7], since fibrosis and obliterative phlebitis is typically not seen, resulting in insensitivity to diagnosis [8]. Kamisawa et al. firstly described histologic feature of IgG4-positive plasma cell infiltration of the BM in two patients with AIP in 2003 [9]. Moreover, in a case report of isolated IgG4-RKD with kappa light chain deposit, BM biopsy revealed around 20% of plasma cell infiltration without monoclonal paraprotein [8]. As reported in published studies, BM involvement of IgG4-RD usually presented pancytopenia, accompanied by other hematologic manifestations, including lymphadenopathy, eosinophilia and polyclonal hypergammaglobulinemia [6], and was finally confirmed by subsequent BM pathology. In addition, a case of IgG4-RD primarily presenting as multiple vertebral BM lesions on MR imaging and 18F-FDG-PET/CT [10], was finally identified IgG4-related BM involvement by pathology. A recently published PET/CT research by Schmидkonz et al. [11] declared that lesions with high uptake in 18F-FDG-PET/CT showed dense lymphoplasmacytic

Literature search

A systematic review of the literature was done of IgG4-RD with involvement of bone marrow published before September 2021 on PubMed/MEDLINE. Our search included a combination of keywords such as, “IgG4-related disease”, “bone marrow”, “thrombocytopenia”, “leukopenia” and “anemia”. Our search was limited to English articles including original articles, review articles and case reports. Reported hematologic presentations which were irrelevant to IgG4-RD or did not contain detailed information were excluded.
infiltration of IgG4 cells in histology; and that fibroblast activation protein imaging could disentangle inflammatory from fibrotic disease activity. In the current study, we reported one patient (#1) showing IgG4-dominated plasma cells infiltration in BM, with no hypermetabolic lesion found in FDG-PET/CT. For another patient (#2), we identified elevated FDG uptake lesions involving multi-bone marrow in the context of the active IgG4-RD. Reported cases of definite IgG4-related bone marrow involvement were rare as listed in Table 2. A recent flow cytometric analysis found different immunophenotyping of atypical plasma cells in peripheral blood (accounting for 58.3%, expressing CD19<sup>low</sup>/CD38<sup>+</sup>/CD138<sup>dim</sup>/CD56<sup>−</sup>/CD45<sup>+</sup>) and in the BM (accounting for 64.3%, expressing CD19<sup>low</sup>/CD38<sup>+</sup>/CD138<sup>+</sup>/CD56<sup>+</sup>/CD45<sup>low</sup>) [12]. As an adhesion molecule, the difference in CD56 expression might be related to the migration ability to the circulating system. However, the exact explanation was unclear.

Lymphadenopathy is the common presentation in IgG4-RD. Involved lymph nodes typically have >100 IgG4-positive cells/HPF with an IgG4/IgG ratio > 40%. In addition, some pathologists have noticed ectopic germinal centers formed in IgG4-RD affected tissues and their possible relationship with dense deposits along tubular basement membrane [13, 14], as findings showed in our case #1. Peripheral lymph tissues mainly include lymph nodes and mucosa-associated lymphoid tissue where circulating plasmablasts, an indicator of IgG4-RD disease activity, further differentiate and proliferate to form mature plasma cells and produce antibodies [15]. And tissue-resident antibody-secreting plasma cells are the major interstitial infiltrating inflammation cells. As reported in many clinical studies, serum IgG4 level correlates with lymph node involvement and the number...
| No. | Author | Age range (years) | Race, gender | Extra-hematologic organs involved in IgG4-RD | Presentation of hematologic involvement | Detection of bone marrow involvement | Treatment | Prognosis |
|-----|--------|-------------------|--------------|------------------------------------------|--------------------------------------|---------------------------------|----------|-----------|
| 1   | Kim [12] | 60–65             | Korean, M    | Kidney: IgG4-related tubulointerstitial nephritis; Skin: rash (possible associated with eosinophilia) | Multiple lymphadenopathies; leukocytosis; thrombocytopenia, marked eosinophilia (51%), and rare nucleated red blood cells (1/100 WBCs) | FDG-PET/CT: hyperactive BM; BM biopsy: 20.4% eosinophils; 16.8% immature plasma cells; increased numbers of CD138-positive plasma cells; IgG4/IgG-positive plasma cell ratio = 0.88 PB: 58.3% of plasma cells were atypical (low CD19 expression with CD38+/CD138+/CD56−/CD45+) | High-dose steroids | Symptoms improved |
| 2   | Ichiki [7] | 60–65             | Japanese, F  | Submandibular gland swelling              | Anemia, IgG4-related lymphadenopathies by lymph node biopsy | FDG-PET/CT: uptakes in multiple bones and immunohistochemically proven by BM biopsy; BM biopsy: >50% of CD138-positive plasma cells were IgG4 positive | Steroids 0.5 mg/kg | Anemia and submandibular gland swelling improved |
| 3   | van den Elshout-den Uyl [10] | 75–80             | Netherland, M | Fatigue, increased exhaustion after physical exercise, weight loss, and night sweats | Anemia and leucocytosis | MRI showed multiple hypodense bone lesions; FDG-PET/CT: FDG-avid bone lesions along the spinal cord; BM biopsy: <10% plasma cells in pre-existing bone marrow, but around 25% plasma cells were present in the fibrotic lesion | Prednisolone starting dose 40 mg/day | Symptoms improved, as well as serum hemoglobin and ESR |
| 4   | Tarte [33] | 40–45             | African-American, M | Kidneys (TIN, imaging abnormalities), lungs, liver, and small intestine (imaging abnormalities) | Lymphadenopathies (biopsy-proven), anemia and thrombocytopenia | BM biopsy: mild plasmacytosis (10–15% of total cellularity), a subset of plasma cells exhibited specificity for IgG4+ staining (<40% of total IgG+ plasma cells) | Prednisone 60 mg/day, Rituximab | Symptoms improved |
| 5   | Chinese, M | 65–70             | Chinese, M   | Kidneys (IgG4-TIN, imaging abnormalities), submaxillary glands, arteritis | Leukopenia, anemia and thrombocytopenia, lymphadenopathies | BM biopsy: 50% of CD138-positive plasma cells were IgG4-positive, scattered eosinophils | Prednisone 40 mg/day | Symptoms improved |
Table 2 (continued)

| No. | Author | Age range (years) | Race, gender | Extra-hematologic organs involved in IgG4-RD | Presentation of hematologic involvement | Detection of bone marrow involvement | Treatment | Prognosis |
|-----|--------|-------------------|--------------|---------------------------------------------|----------------------------------------|-------------------------------------|-----------|-----------|
| 6   |        | 35-40             | Chinese, M   | Kidneys (IgG4-TIN), submandibular gland    | Marked eosinophilia (15%), lymphadenopathies | FDG-PET/CT: hyperactive BM           | Prednisone 50 mg/day, Rituximab   | Symptoms improved |

5 and 6 are our presented cases

PB peripheral blood, BM bone marrow, MRI magnetic resonance imaging, TIN tubulointerstitial nephritis
of affected organs. IgG4-RD may also be related to the occurrence of hematologic tumors. The elevated level of plasmablasts from continuously stimulated B lymphocytes, which reflects the IgG4-RD inflammation severity, might lead to B lymphocyte lymphoma. A previous study reported a special case [16] of extranodal marginal zone B cell lymphoma in the background of IgG4-RD, with malignant tumor cells existing in the presence of non-neoplastic cells. Moreover, in the differentiation process, plasmablasts are possibly transformed into tumorous plasma cells producing numerous monoclonal IgG4 molecules. This supports the comment that once a high level of serum IgG4 was found, monoclonal IgG4 must be excluded. There have been case reports of IgG4 myeloma being mistaken for IgG4-RD [17–19], as well as IgG4 POEMS syndrome [20]. These provide proof that the IgG4 molecule is likely a reactive product of immune dysregulation rather than the primary etiologic mediator in IgG4-RD.

Eosinophilia and tissue eosinophils infiltration are common in IgG4-RD. Eosinophilic angiocentric fibrosis is now part of IgG4-RD, usually affecting orbits and the upper respiratory tract. In the current report, renal eosinophils aggregation was obvious in both patients, even with an absence of eosinophilia as in case#1. A previous study presented similar findings that eosinophils infiltration was evident in 30.8% of IgG4-RD patients compared with 9.5% in non-IgG4 tubulointerstitial nephritis [21]. Regulation of IgG4 production is dependent on Th2 cells and is therefore linked to IgE response and eosinophilia, indicating an underlying inflammation. However, the role of eosinophils in immune-mediated IgG4-RD is not completely understood. In some recently published studies [21–23], the significance of eosinophils to renal fibrosis progression has been focused on. And in animal models, the loss of eosinophil peroxidase could reduce renal fibrosis [23]. All these evidence suggest that eosinophils may represent the inherent characteristic of the immune response in IgG4-RD [24, 25]. Sometimes, IgG4-RD with eosinophilia needs to be differentiated from lymphocyte variant hypereosinophilic syndrome and autoimmune lymphoproliferative syndrome, because both diseases could present eosinophilia and involve the lymph nodes [26, 27].

Disease diagnosis and monitoring based on clinical syndromes and general imaging findings are currently required criteria. Pathological examination of involved tissue remains irreplaceable in the diagnosis of IgG4-RD. While in the absence of pathological evidence, it is difficult to accurately distinguish inflammatory from fibrotic activity in human immune-mediated disease in vivo. 18F-FDG-PET/CT has been considered a promising diagnostic tool to aid IgG4-RD diagnosis in recent years. As a whole-body imaging technique, it is reported to detect more lesions in 71.4% of IgG4-RD patients than the conventional imaging methods, providing a more comprehensive evaluation of disease distribution as an entity [27]. In another reported study, 18F-FDG-PET/CT had a sensitivity of 85.7% and specificity of 66.1% for diagnosing IgG4-RD [28]. The intensity of 18F-FDG uptake in IgG4-RD changes along with disease remission and relapse [29]. Although the difference in cutoff SUV values between IgG4-RD and early-stage malignancies is not significant, there are still recognizable characteristics [27], such as the distribution characteristics of hypermetabolic lesions, contributing to a more accurate judgment. Patient #1 showed prominent IgG4-positive plasma cells infiltration in the bone marrow and arteritis on enhanced-CT, but 18F-FDG-PET/CT did not show high uptake in both sites. It was speculated that 18F-FDG might not be able to visualize chronic fibrotic lesions. At present, more novel PET probes have been exploited to better target fibrotic lesions (i.e., 68FAPI) [11] or to detect early changes in lymphoid mass in systemic autoimmunity (i.e., 18F-fluoroarabinofuranosyl cytosine) [30]. This would allow evidence for a more accurate evaluation of immunosuppressive therapy.

Steroids are still the mainstay for IgG4-RD therapy. However, its long-term use is not recommended. B cells depletion strategy is superior to steroids, especially for refractory and recurrent cases. Rituximab has shown a response rate of 97% in one prospective trial [31] and a lower relapse rate [32]. In case#1, steroids helped to reach partial remission of renal injury and systemic inflammation. His kidney function finally remained at chronic kidney disease stage 4. Oppositely, case #2 was young and diagnosed with early onset of disease, plasma exchange combined with steroids plus Rituximab led to complete remission.

**Conclusion**

These two cases illustrate the rare bone marrow involvement in active IgG4-RD accompanied by other hematologic syndromes. The significance of disease pathogenesis is worthy of further study.

**Acknowledgements**

None.

**Authors’ contributions**

SYL contributed to patient management, diagnosis, and manuscript drafting. HW contributed to patient pathological diagnosis and manuscript drafting. TS contributed to clinical data collection, analysis, interpretation, and intellectual content of critical importance to the work described. All authors had the opportunity to revise the manuscript. We gratefully thank LK and KW for investigating the 18F-FDG-PET/CT and enhanced-CT figures. All authors thank the patients and their families for their support. All authors read and approved the final manuscript.
Funding
This study was supported by grants from the National Science and Technology Major Projects for major new drugs innovation and development (2017ZX09304028). The funding supported the long-term follow-up of these patients. The funding body had no role in study design, data collection and analysis, decision to publish, or manuscript preparation.

Availability of data and materials
The patients were regularly followed up and the clinical data are traceable. The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Patient consent was obtained for publication.

Competing interests
The authors declare they have no competing interests.

Author details
1 Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China. 2 Institute of Nephrology, Peking University, Beijing, China. 3 Renal Division, Department of Medicine, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China. 4 Laboratory of Electron Microscopy, Peking University First Hospital, Beijing, China.

Received: 6 November 2021   Accepted: 13 January 2022

Published online: 02 February 2022

References
1. Kamisawa T, Zen Y, Pillai S, Stone HJ. IgG4-related disease. Lancet. 2015;385(9976):1460–71.
2. Blockmans D. IgG4-related disease. Acta Clin Belg. 2018;73(1):11–5.
3. Zhao EJ, Cheng CV, Mattman A, Chen LYC. Polyclonal hypergammaglobulinemia: assessment, clinical interpretation, and management. Lancet Haematol. 2021;8(3):e365–75.
4. Harkness T, Fu X, Zhang Y, Choi HK, Stone JH, Blumenthal KJ, et al. Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race. Ann Allergy Asthma Immunol. 2020;125(2):190–5.
5. Qi R, Chen LY, Park S, Irvine R, Seidan MA, Kelsall JT, et al. Utility of serum IgG4 levels in a multiethnic population. Am J Med Sci. 2018;354(1):161–6.
6. Ichiki A, Hashimoto N, Ueda T, Hiroiwa S, Tajiri T, Nakamura N, et al. IgG4-related disease with bone marrow involvement. Intern Med. 2016;55(16):2295–9.
7. MaoBo Khail MA, Rajput AS, Ghani R, Ullah SMR, Thet MK, DaiwaiNA RG, et al. Isolated renal involvement by IgG4-related disorder mimicking multiple myeloma, a diagnosis not to miss. Saudi J Kidney Dis Transpl. 2021;32(1):249–54.
8. Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003;38(10):982–4.
9. van den Elshout-den UD, Spoto CPE, de Boer M, Leiner T, Leavis HL, Leguit RJ. First report of IgG4-related disease primary presenting as vertebral bone marrow lesions. Front Immunol. 2019;10:1910.
10. Schmidkonz C, Rauber S, Atzinger A, Agarwal R, Goto T, Soare A, et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis. 2020;79(11):1485–91.
11. Kim HJ, You E, Hong S, Park CJ. A Case of IgG4-related Disease with bone marrow involvement: bone marrow findings and flow cytometric immunophenotyping of plasma cells. Ann Lab Med. 2021;41(2):243–6.
12. Sato Y, Inoue D, Asano N, Takata K, Asakhu H, Maeda Y, et al. Association between IgG4-related disease and progressively transformed germinal centers of lymph nodes. Mod Pathol. 2012;25(7):7956–67.
13. Wang H, Su T, Li DY, et al. Clinical significance and pathological features of ectopic lymphoid-like structures in IgG4-related tubulointerstitial nephritis. Chin J Nephrol. 2019;35(9):641–7.
14. Wallace ZS, Mattao H, Carruthers M, Mahajan VS, Torre ED, Lee H, et al. Plasma blasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015;74(1):190–5.
15. Harada K, Otsuka F. Cardiac mucosa-associated lymphoid tissue lymphoma involved in IgG4-related disease. Eur Heart J. 2019;41(15):1519.
16. Gaurain DTV, Marcon KM, DeMarco ML, Fung AWS, van der Gugten G, Mattman A, et al. IgG4 plasma cell myeloma without clinical evidence of IgG4-related disease: a report of two cases. Hematology. 2020;25(1):335–40.
17. Ito A, Yamauchi T, Nakano A, Fujino M, Ito M. IgG4 plasma cell myeloma: clinicopathological characteristics and diagnosis. Pathol Int. 2020;70(8):551–6.
18. Geyer JT, Nierszko R, Jayaban DS, Matthew S, Subramanyswar M, Geyer AI, et al. IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease. Mod Pathol. 2014;27(3):375–81.
19. Zheng M, Zhou P, Zheng K, Meng L, Liu X, Chu M, et al. A special subtype of POEMS syndrome: IgG4 subtype. Am J Transl Res. 2016;8(2):588–96.
20. Yoshita K, Kawanoo M, Mizushima I, Hara S, Ito Y, Imai N, et al. Light-microscopic characteristics of IgG4-related tubulointerstitial nephritis: distinction from non-IgG4-related tubulointerstitial nephritis. Nephrol Dial Transplant. 2012;27(7):2755–61.
21. Tang A, Okamoto K, Tarit A, Rosengerg AZ, Solman KM, Ploth DW, et al. Esinophilophilia and risk of early stage kidney disease. BMC Nephrol. 2020;21:1(14).
22. Colson S, Luan HY, Liu Y, Meyer C, Gewin L, Bhaye G. Peroxidase and eosinophil peroxidase, but not myeloperoxidase, contribute to renal fibrosis in the murine unilateral ureteral obstruction model. Am J Physiol Renal Physiol. 2019;316(2):F360–71.
23. Della Torre E, Mattao H, Mahajan VS, Carruthers M, Pillai S, Stone HJ. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. Allergy. 2014;69(9):267–72.
24. Saeki T, Kobayashi D, Ito T, Tamura M, Yoshikawa S, Yamazaki H. Comparison of clinical and laboratory features of patients with and without allergic conditions in IgG4-related disease: a single-center experience in Japan. Mod Rheumatol. 2018;28(S):845–8.
25. Carruthers MN, Park S, Slack GW, Dalal BI, Skinnider BF, Schaeffer D, et al. IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: a comparative case series. Eur J Haematol. 2017;98(4):378–87.
26. Zhang J, Chen H, Ma Y, Xiao Y, Niu N, Lin W, et al. Characterizing IgG4-related disease with 18F-FDG PET/CT: a prospective cohort study. Eur J Nucl Med Mol Imaging. 2014;41(8):1624–34.
27. Lee J, Hyun SH, Kim SE, Kim DK, Lee JK, Moon SH, et al. Utility of FDG PET/CT for differential diagnosis of patients clinically suspected of IgG4-related disease. Clin Nucl Med. 2016;41(5):e237–43.
28. Berti A, Della Torre E, Gallivanone F, Canevari C, Milani R, Lanzillotta M, et al. Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. Rheumatology (Oxford). 2017;56(12):2084–92.
29. Radu CG, Shu CJ, Nair-Gill E, Shelly SM, Barro J, Satyamurthy N, et al. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2-deoxyxycidine analog. Nat Med. 2008;14(7):785–8.
30. Masaki Y, Matsui S, Saeki T, Tsuboi H, Hirata S, Izumi Y, et al. A multi-center comparison of clinical and laboratory features of patients with and without IgG4-related disease. Mod Pathol. 2014;27(3):375–81.
31. Masaki Y, Matsui S, Saeki T, Tsuboi H, Hirata S, Izumi Y, et al. IgG4 plasma cell myeloma: clinicopathological characteristics and diagnosis. Pathol Int. 2017;59(10):1594–600.
32. Omar D, Chen Y, Dong L, Cong Y. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis. Rheumatology (Oxford). 2017;56(12):2084–92.
33. Tarte NN, Ravipati CS, Leon de la Rocha JA, Rinker E, Patel NJ. IgG4-related disease with multiorgan involvement: a case-based review. Rheumatol Int. 2021;41(6):1169–74.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.